IL6 and non-small cell lung carcinoma: Further evidence indicates that in NSCLC patients with high PD-L1 expression but poor response to ICIs, the IL-6/JAK/STAT3 signaling pathway is aberrantly activated, with MDSCs identified as the predominant source of IL-6.